|RNS Reach Story|
|Go to market news section|
NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, OR JAPAN OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Sensyne Health Limited
Sensyne Health signs Strategic Research Agreement
with Oxford University Hospitals NHS Foundation Trust
New research collaboration aims to analyse anonymised genetic data using clinical artificial intelligence technology to accelerate medical research, help find new treatments and improve patient care
Oxford, UK; 7 August 2018: Sensyne Health Limited (the "Company"), a British clinical AI technology company, announces today that it has signed a Strategic Research Agreement (SRA) with Oxford University Hospitals NHS Foundation Trust (OUH), under which the Company and the Trust will strengthen the way they work together and expand their collaboration to include the analysis of anonymised genetic data using the Company's clinical artificial intelligence (clinical AI) technology to improve patient care and accelerate medical research.
This agreement builds on an existing relationship with OUH and the University of Oxford signed in July 2017. Under the new agreement announced today, Sensyne Health will work with the Trust to analyse consented and anonymised genetic data, comprising diagnostic genetic tests and whole genome sequences. The agreement covers data that has been generated by the Trust over the past five years as well as data that will be generated over the next 10 years. In addition Sensyne Health will collaborate with the Trust in developing a proposal to use genomic medicine, including whole genome sequencing, which when mobilised could be part of the standard pathway of care for NHS patients of the Trust in future. The purpose of this research is to use clinical AI to analyse the growing set of genotypic and phenotypic clinical data generated by the Trust that is highly valuable for medical research and the development of potential new treatments.
Under this new agreement, OUH receives an additional £5m in equity in Sensyne Health, and will also benefit from royalties that arise from any discoveries, for reinvestment back into the Trust to benefit patients.
Research will be undertaken to the highest standards of information governance and data security in accordance with NHS requirements and data protection legislation. Genome sequencing will only be undertaken with patient consent and for the purposes of research. Patients have the right to decline to be involved should they wish.
Dr Bruno Holthof, CEO, Oxford University Hospitals NHS Foundation Trust, commented: "Oxford University Hospitals is one of the digital centres of excellence in the NHS. Because of our digital investments, we now have a unique database that will grow in size over time and this Strategic Research Agreement will allow us to find new ways of treating our patients."
Lord (Paul) Drayson, CEO of Sensyne Health, commented: "Sensyne Health is developing, in collaboration with the University of Oxford and with Oxford University Hospitals, world-leading capability in the use of clinical AI to analyse anonymised patient data. This new agreement, enabling the analysis of linked genotypic and phenotypic data, will further enhance our ability to make new discoveries and develop new treatments."
For more information please contact:
T: +44 (0) 330 058 1845 | M: +44 (0)7899 061975
Oxford University Hospitals NHS Foundation Trust
T: +44 (0) 1865 572984
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 20 3709 5700
Notes for editors:
About Sensyne Health
Sensyne Health is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with the Caldicott Principles, UK data protection law and applicable regulatory guidance.
Sensyne Health, which recently changed its name from Drayson Health, is based in the Big Data Institute at the University of Oxford's Old Road Campus.
For more information, please visit: www.sensynehealth.com
About Oxford University Hospitals NHS Foundation Trust
Oxford University Hospitals NHS Foundation Trust (OUH) is one of the largest acute teaching trusts in the UK, with a national and international reputation for the excellence of its services and its role in patient care, teaching and research.
The Trust supports world-leading research programmes in cardiovascular diseases, musculoskeletal disorders, neurological disorders such as Parkinson's and Alzheimer's through its designation as one of the UK's five comprehensive biomedical centres. It works in close partnership with the University of Oxford and is a leading centre for cancer, neurosciences, diabetes, genetics and many other fields. Research themes of particular strength are: cancer, cardiovascular science, diabetes, endocrinology & metabolism, infection and immunology, musculoskeletal science, neuroscience and reproduction and development.
This brings together academic research expertise with clinical teams to translate medical science into better healthcare treatments. Our patients benefit from world-class discovery and innovation supported by the NIHR Oxford Biomedical Research Centre, a partnership between the Trust and the University of Oxford, funded by the National Institute for Health Research.
The Trust employs over 12,000 staff and consists of four hospitals: the Churchill Hospital, John Radcliffe Hospital and Nuffield Orthopaedic Centre in Oxford and the Horton General Hospital in Banbury. On 1 October 2015 the Trust was awarded Foundation status and became Oxford University Hospitals NHS Foundation Trust. www.ouh.nhs.uk
What is 'clinical AI'?
Clinical AI is a highly specialised field of AI which uses machine learning algorithms, including deep learning, in tandem with human clinical expertise and big datasets with which to train the algorithms. Clinical AI is particularly concerned with the analysis of data acquired during routine clinical care of patients, in order to derive clinically-useful results such as to improve patient outcomes and to discover new insights about the use of pharmaceutical compounds to treat patients.
What is 'genomic medicine'?
Genomic medicine is a field of study that leverages the recent advances in our ability to study the entire genome of patients as a part of their clinical care, as opposed to the more traditional methods of studying small sections of a patient's genetic information. Using a patient's genomic information can advance diagnosis, treatment and predictive health, help to unlock the promise of personalised medicine, and even inform drug discovery.
Whole Genome Sequencing (WGS) is the process of determining the complete DNA sequence of an organism's genome. The genome is the entire set of genetic information that - in concert with the environments they have experienced - has made an individual who they are. Genomic medicine studies how that set of information differs from person to person and how that relates to their health and medical care. WGS will be conducted for the purposes of research and for the development of personalised therapies for patients treated at the Oxford University Hospitals NHS Foundation Trust.
This announcement does not constitute or form part of an offer to sell or issue or a solicitation of an offer to subscribe for or buy any securities nor should it be relied upon in connection with any contract or commitment whatsoever.
These materials are not an offer of securities for sale in the United States. The securities to which these materials relate have not been registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of the securities in the United States.
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
|©London Stock Exchange plc. All rights reserved|